These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 15150261)

  • 1. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
    Colvin RA; Campanella GS; Sun J; Luster AD
    J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11.
    Dagan-Berger M; Feniger-Barish R; Avniel S; Wald H; Galun E; Grabovsky V; Alon R; Nagler A; Ben-Baruch A; Peled A
    Blood; 2006 May; 107(10):3821-31. PubMed ID: 16368892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR3 requires tyrosine sulfation for ligand binding and a second extracellular loop arginine residue for ligand-induced chemotaxis.
    Colvin RA; Campanella GS; Manice LA; Luster AD
    Mol Cell Biol; 2006 Aug; 26(15):5838-49. PubMed ID: 16847335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands.
    Clark-Lewis I; Mattioli I; Gong JH; Loetscher P
    J Biol Chem; 2003 Jan; 278(1):289-95. PubMed ID: 12417585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation.
    Xanthou G; Williams TJ; Pease JE
    Eur J Immunol; 2003 Oct; 33(10):2927-36. PubMed ID: 14515277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
    Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
    J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection.
    Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G
    Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11.
    Xanthou G; Duchesnes CE; Williams TJ; Pease JE
    Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).
    Sauty A; Colvin RA; Wagner L; Rochat S; Spertini F; Luster AD
    J Immunol; 2001 Dec; 167(12):7084-93. PubMed ID: 11739530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties.
    Proost P; Schutyser E; Menten P; Struyf S; Wuyts A; Opdenakker G; Detheux M; Parmentier M; Durinx C; Lambeir AM; Neyts J; Liekens S; Maudgal PC; Billiau A; Van Damme J
    Blood; 2001 Dec; 98(13):3554-61. PubMed ID: 11739156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.
    Heise CE; Pahuja A; Hudson SC; Mistry MS; Putnam AL; Gross MM; Gottlieb PA; Wade WS; Kiankarimi M; Schwarz D; Crowe P; Zlotnik A; Alleva DG
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1263-71. PubMed ID: 15761110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of rat I-TAC/CXCL11/SCYA11 during central nervous system inflammation: comparison with other CXCR3 ligands.
    McColl SR; Mahalingam S; Staykova M; Tylaska LA; Fisher KE; Strick CA; Gladue RP; Neote KS; Willenborg DO
    Lab Invest; 2004 Nov; 84(11):1418-29. PubMed ID: 15322564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts.
    Kouroumalis A; Nibbs RJ; Aptel H; Wright KL; Kolios G; Ward SG
    J Immunol; 2005 Oct; 175(8):5403-11. PubMed ID: 16210647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3.
    Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE
    Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optic neuritis: chemokine receptor CXCR3 and its ligands.
    Sørensen TL; Roed H; Sellebjerg F
    Br J Ophthalmol; 2004 Sep; 88(9):1146-8. PubMed ID: 15317705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMR structure of CXCR3 binding chemokine CXCL11 (ITAC).
    Booth V; Clark-Lewis I; Sykes BD
    Protein Sci; 2004 Aug; 13(8):2022-8. PubMed ID: 15273303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3.
    Scholten DJ; Canals M; Wijtmans M; de Munnik S; Nguyen P; Verzijl D; de Esch IJ; Vischer HF; Smit MJ; Leurs R
    Br J Pharmacol; 2012 Jun; 166(3):898-911. PubMed ID: 21883151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
    Karin N
    Front Immunol; 2020; 11():976. PubMed ID: 32547545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.
    Belperio JA; Keane MP; Burdick MD; Lynch JP; Xue YY; Li K; Ross DJ; Strieter RM
    J Immunol; 2002 Jul; 169(2):1037-49. PubMed ID: 12097412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
    Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
    J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.